Treatment of melanoma-bearing mice with acriflavine, reported to prevent HIF-1α/HIF-1β heterodimerization, improved immunotherapy strategies based on TRP-2 peptide vaccination and anti-PD-1 antibody. This evidence concerns the gene HIF1A and melanoma.